Description
ECULAZUMAB (SOLIRIS) 10MG/ML X8
First action · last action
2016-02-29 · 2016-03-01
Transactions
2
First transaction's obligation
$35,317
Base + all options value (sum of deltas)
$35,840
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D30015
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2016-02-29+$35,317= $35,317
- Mod P000012016-03-01+$523= $35,840
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2016-02-29 | +$35,317 | $35,317 | ECULAZUMAB (SOLIRIS) 10MG/ML X8 |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2016-03-01 | +$523 | $35,840 | ECULAZUMAB (SOLIRIS) 10MG/ML X8 |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DKCXLGANZAN3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79726A0021 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C24526N0739 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $104,650 | FY2026 |
| 36F79726D0143 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C26026F0055 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $1,255,805 | FY2026 |
| 36C26025F0093 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $626,866 | FY2025 |
| 36C26024F0096 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $522,487 | FY2024 |
Other recipients under 6505 from 553-DETROIT (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25116F1203 | ACTELION PHARMACEUTICALS US, INC. | 553-DETROIT | $4,614 | FY2016 |
| VA25116F1198 | PFIZER INC | 553-DETROIT | $11,065 | FY2016 |
| VA25116F0598 | PFIZER INC | 553-DETROIT | $11,065 | FY2016 |
| VA25116F0445 | ACTELION PHARMACEUTICALS US, INC. | 553-DETROIT | $4,614 | FY2016 |
| VA25116F0281 | ACTELION PHARMACEUTICALS US, INC. | 553-DETROIT | $4,614 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25116F1088_3600_V797D30015_3600 · retrieved 2026-09-26.